Gemma Carreras-Badosa

Gemma Carreras-Badosa

Auto-generated profile, based on publicly available information

Gemma Carreras-Badosa

Departament de Biologia Facultat de Ciències Universitat de Girona Girona Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in Pediatric Research
Verified
Journal Article
Closed access
JBJudit Bassols
Judit Bassols
Matteo SerinoMatteo Serino
Matteo Serino
GCGemma Carreras-Badosa
Gemma Carreras-Badosa
RBRémy Burcelin
Rémy Burcelin
VBVincent Blasco-Baque
Vincent Blasco-Baque
JFJosé M. Fernandez-Real
José M. Fernandez-Real

1 November 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
GCGemma Carreras-Badosa
Gemma Carreras-Badosa
ABAlexandra Bonmatí
Alexandra Bonmatí
FOFrancisco Jose Ortega
Francisco Jose Ortega
JMJosep-Maria Mercader
Josep-Maria Mercader
MGMarta Guindo-Martínez
Marta Guindo-Martínez
JBJudit Bassols
Judit Bassols
Context: MicroRNAs (miRNAs) are valuable circulating biomarkers and therapeutic targets for metabolic diseases. Objective: The objective of the study was to define the pattern of circulating miRNAs in pregestational and gestational obesity and to explore their associations with maternal metabolic parameters and with markers for pre- and postnatal growth. Design, Settings, and Main Outcome Measure: TaqMan low-density arrays were used to profile plasma miRNAs in six women with pregestational obesity (PregestOB), six with gestational obesity (GestOB), and six with normal pregnancies (control) during the second trimester of gestation. The most relevant miRNAs were validated in 70 pregnant women (20 PregestOB, 25 GestOB, and 25 control). Maternal metabolic parameters including glucose, glycated hemoglobin, homeostasis model assessment index of insulin resistance, C-peptide, and lipids were assessed. Placentas were weighed at delivery and newborns also during 6 months of life. Results: We identified 13 circulat...

12 November 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MZMin Zhao
Min Zhao
ALAbel López-Bermejo
Abel López-Bermejo
CCCarmelo A. Caserta
Carmelo A. Caserta
CMCarla Campos Muniz Medeiros
Carla Campos Muniz Medeiros
Anastasios KolliasAnastasios Kollias
Anastasios Kollias
MRMilena Cavalcanti Ramalho
Milena Cavalcanti Ramalho
OBJECTIVE: It has been argued that metabolically healthy obesity (MHO) does not increase cardiovascular disease (CVD) risk. This study examines the association of MHO with carotid intima-media thickness (cIMT), a proxy of CVD risk, in children and adolescents. RESEARCH DESIGN AND METHODS: Data were available for 3,497 children and adolescents aged 6–17 years from five population-based cross-sectional studies in Brazil, China, Greece, Italy, and Spain. Weight status categories (normal, overweight, and obese) were defined using BMI cutoffs from the International Obesity Task Force. Metabolic status (defined as “healthy” [no risk factors] or “unhealthy” [one or more risk factors]) was based on four CVD risk factors: elevated blood pressure, elevated triglyceride levels, reduced HDL cholesterol, and elevated fasting glucose. High cIMT was defined as cIMT ≥90th percentile for sex, age, and study population. Logistic regression model was used to examine the association of weight and metabolic status with high cIMT, with adjustment for sex, age, race/ethnicity, and study center. RESULTS: In comparison with metabolically healthy normal weight, odds ratios (ORs) for high cIMT were 2.29 (95% CI 1.58–3.32) for metabolically healthy overweight and 3.91 (2.46–6.21) for MHO. ORs for high cIMT were 1.44 (1.03–2.02) for unhealthy normal weight, 3.49 (2.51–4.85) for unhealthy overweight, and 6.96 (5.05–9.61) for unhealthy obesity. CONCLUSIONS: Among children and adolescents, cIMT was higher for both MHO and metabolically healthy overweight compared with metabolically healthy normal weight. Our findings reinforce the need for weight control in children and adolescents irrespective of their metabolic status.

20 March 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
GCGemma Carreras-Badosa
Gemma Carreras-Badosa
ABAlexandra Bonmatí
Alexandra Bonmatí
FOFrancisco Jose Ortega
Francisco Jose Ortega
JMJosep-Maria Mercader
Josep-Maria Mercader
MGMarta Guindo-Martínez
Marta Guindo-Martínez
JBJudit Bassols
Judit Bassols
Context: Human placenta exhibits a specific microRNA (miRNA) expression pattern. Some of these miRNAs are dysregulated in pregnancy disorders such as preeclampsia and intrauterine growth restriction and are potential biomarkers for these pathologies. Objective: To study the placental miRNA profile in pregnant women with pregestational overweight/obesity (preOB) or gestational obesity (gestOB) and explore the associations between placental miRNAs dysregulated in maternal obesity and prenatal and postnatal growth. Methods: TaqMan Low Density Arrays and real-time polymerase chain reaction were used to profile the placental miRNAs in 70 pregnant women (20 preOB, 25 gestOB, and 25 control). Placentas and newborns were weighed at delivery, and infants were weighed at 1, 4, and 12 months of age. Results: Eight miRNAs were decreased in placentas from preOB or gestOB (miR-100, miR-1269, miR-1285, miR-181, miR-185, miR-214, miR-296, and miR-487) (all P < 0.05). Among them, miR-100, miR-1285, miR-296, and miR-487 were associated with maternal metabolic parameters (all P < 0.05) and were predictors of lower birth weight (all P < 0.05; R2 > 30%) and increased postnatal weight gain (all P < 0.05; R2 > 20%). In silico analysis showed that these miRNAs were related to cell proliferation and insulin signaling pathways. miR-296 was also present in plasma samples and associated with placental expression and prenatal and postnatal growth parameters (all P < 0.05). Conclusions: We identified a specific placental miRNA profile in maternal obesity. Placental miRNAs dysregulated in maternal obesity may be involved in mediation of growth-promoting effects of maternal obesity on offspring and could be used as early markers of prenatal and postnatal growth.

1 December 2020 in Biomaterials
Verified
Journal Article
Closed access
GCGemma Carreras-Badosa
Gemma Carreras-Badosa
JMJulia Maslovskaja
Julia Maslovskaja
KPKapilraj Periyasamy
Kapilraj Periyasamy
EUEgon Urgard
Egon Urgard
KPKärt Padari
Kärt Padari
ARAna Rebane
Ana Rebane

6 June 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
HVHelen Vaher
Helen Vaher
TRToomas Runnel
Toomas Runnel
EUEgon Urgard
Egon Urgard
AAAlar Aab
Alar Aab
GBGemma Carreras Badosa
Gemma Carreras Badosa
ARAna Rebane
Ana Rebane